Literature DB >> 25189665

Type 2 Endoleaks Post-EVAR: Current Evidence for Rupture Risk, Intervention and Outcomes of Treatment.

Raymond Chung1, Robert A Morgan.   

Abstract

Type 2 endoleaks (EL2) are the most commonly encountered endoleaks following EVAR. Despite two decades of experience, there remains considerable variation in the management of EL2 with controversies ranging from if to treat, when to treat and how to treat. Here, we summarise the available evidence, describe the treatment techniques available and offer guidelines for management.

Entities:  

Mesh：

Year:  2014        PMID： 25189665     DOI： 10.1007/s00270-014-0987-x

Source DB:  PubMed          Journal:  Cardiovasc Intervent Radiol        ISSN： 0174-1551            Impact factor:   2.740


  5 in total

Review 1.  [Endovascular aortic repair of endoleaks : Diagnosis, treatment, and outcomes].

Authors:  Sven Rudolf Hauck; Rüdiger Schernthaner; Theresa-Marie Dachs; Maximilian Kern; Martin Funovics
Journal:  Radiologie (Heidelb)       Date:  2022-06-23

2.  Chronological Change of the Sac after Endovascular Aneurysm Repair.

Authors:  Min Hyun Kim; Hyung Sub Park; Sanghyun Ahn; Sang-Il Min; Seung-Kee Min; Jongwon Ha; Taeseung Lee
Journal:  Vasc Specialist Int       Date:  2016-12-31

Review 3.  Type II endoleaks: challenges and solutions.

Authors:  Andrew Brown; Greta K Saggu; Matthew J Bown; Robert D Sayers; David A Sidloff
Journal:  Vasc Health Risk Manag       Date:  2016-03-02

Review 4.  Techniques and future perspectives for the prevention and treatment of endoleaks after endovascular repair of abdominal aortic aneurysms.

Authors:  Gianluigi Orgera; Marcello Andrea Tipaldi; Florindo Laurino; Pierleone Lucatelli; Alberto Rebonato; Ioannis Paraskevopoulos; Michele Rossi; Miltiadis Krokidis
Journal:  Insights Imaging       Date:  2019-09-23

Review 5.  Secondary Endoleak Management Following TEVAR and EVAR.

Authors:  Seyed Ameli-Renani; Vyzantios Pavlidis; Robert A Morgan
Journal:  Cardiovasc Intervent Radiol       Date:  2020-08-10       Impact factor: 2.740
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.